

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 23, 2003

HAEMONETICS CORPORATION

(Exact Name of Registrant as Specified in its Charter)

Massachusetts	1-10730	04-2882273
-----	-----	-----
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification Number)

400 Wood Road	
Braintree, MA	02184
-----	-----

(Address of principal executive offices)	(Zip Code)
--	------------

Registrant's telephone number, including area code (781) 848-7100

Item 9. Regulation FD Disclosure.

The following information is intended to be included under "Item 12. Results of Operations and Financial Condition" and is included under this Item 9 in accordance with SEC Release No. 33-8216.

On April 23, 2003, Haemonetics Corporation (the "Company") issued a press release regarding its financial results for the quarter ended and fiscal year ended March 29, 2003 and outlook for fiscal 2004. The Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

On April 23, 2003, we announced our financial results for the quarter and fiscal year ended March 29, 2003, and certain other information. The press release, which has been attached as Exhibit 99.1 discloses two different types of non-GAAP financial measures; a) "as adjusted" operating expenses, operating income, income before taxes, tax expense and net income and b) constant currency comparisons. Both of these are considered non-GAAP financial measures as defined under SEC rules. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with generally accepted accounting principles. In order to fully assess our financial operating results, management believes that these "as adjusted" and constant currency figures are both valuable in evaluating our operating performance. With the "as adjusted" figures, management tries to improve the comparability of operating performance by excluding special items that are outside our normal core operations. Foreign currency has a significant effect on our business and management needs to be able to isolate its effect. However, all non-GAAP measures should be considered in addition to, and not as a substitute for, or superior to, operating income or other measures of financial performance prepared in accordance with generally accepted accounting principles as more fully discussed in our financial statements and filings with the SEC. These non-GAAP measures included in our press release have been reconciled to the nearest GAAP measure as is now required under new SEC rules regarding the use of non-GAAP financial measures.

As used herein, "GAAP" refers to accounting principles generally accepted in the United States

Exhibits

99.1 Press Release, dated April 23, 2003, of Haemonetics

Corporation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION

Date: April 23, 2003

By: s/ Ronald J. Ryan

Ronald J. Ryan, Senior Vice President
and Chief Financial Officer

FOR RELEASE:
Date: April 23, 2003
Time: 5:00pm

CONTACT:
Lisa Lopez
Tel. (781) 356-9517
Alternate Tel. (617) 320-2401
fallon@haemonetics.com

HAEMONETICS ANNOUNCES FINANCIAL RESULTS AND FISCAL YEAR OUTLOOK

Braintree, MA, April 23, 2003 - Haemonetics Corporation today announced earnings per share of \$0.18 and \$1.13 for its fourth quarter and fiscal year ended March 29, 2003, respectively. Revenues for the fourth quarter and fiscal year were \$80.9 million and \$337 million, respectively. During fiscal 2003 Haemonetics repurchased 1.85 million shares for a total of \$50 million(1). The Company also gave financial guidance for fiscal 2004 and announced a new policy with respect to providing forward-looking financial guidance.

The Company has decided to suspend its 10b5-1 stock repurchase plan under which automatic share purchases are made. The Board authorization, with \$26 million remaining, continues in effect. However, the Company's focus at this time is to preserve cash for business development opportunities that, the Company believes, offer greater potential for enhancing long-term shareholder value.

Fourth Quarter Analysis

For the fourth quarter of fiscal 2003, the Company reported net income of \$4.5 million, or \$0.18 per diluted share, compared to \$7.7 million, or \$0.29 per diluted share, in the fourth quarter last year. As anticipated and previously disclosed, foreign exchange adversely affected the quarter by \$0.11(2). Operating income for the fourth quarter was \$6.1 million, versus \$11.2 million in the same quarter last year. Total revenues reached \$80.9 million in the quarter, up 2.3% from \$79.1 million in the year-ago period.

Released amounts are not calculated in accordance with U.S. GAAP. Under newly released guidance by the SEC these results are reconciled to U.S. GAAP in the attached financial summary.

Earnings for the quarter were lower than previously expected due to slower-than-anticipated plasma revenue. The growth rates in plasma have returned to historical low single digits levels. With inventories of "source" plasma remaining high, plasma collections have slowed, resulting in weakness across the industry. Plasma disposables grew 2% in the quarter.

Also impacting slower revenue growth was the Company's cardiovascular surgical cell salvage business. While OrthoPAT(T) system revenues to Haemonetics were flat for the quarter as the Company completes its product enhancement program, end user usage increased by 50%. Surgical disposables growth was 2.5% for the quarter.

Acceptance of automated red cell collection continues to grow, with the Company's Red Cell Index (which tracks automated collections within a group of early adopters) increasing to 11.9% for the quarter from 10.8% in Q3:03(3). Haemonetics technology is now deployed to collect red cells in seven of the 36 American Red Cross regions; two regions rolled out programs in the fourth quarter. Red cell disposables growth for the quarter was 51%.

The Company will discontinue reporting on the Red Cell Index after Q4:03 as the Index has grown above its original 10% target, showing "mainstream" adoption of the technology by early adopters within two years.

Fiscal 2003 Highlights

For fiscal year 2003, the Company reported a revenue increase of 5.3% to \$337 million from \$320 million in fiscal 2002. Net income was \$28.4 million, or \$1.13 per diluted share, compared to \$37.2 million, or \$1.37 per diluted share, both as adjusted, in fiscal 2002(2). Foreign exchange adversely affected earnings per share for the year by \$0.34(2).

Brad Nutter, Haemonetics' newly elected President and Chief Executive Officer, commented, "The Company's results for the year were highlighted by strong performance in a number of its market leading product lines and operational changes were made to lay groundwork for future growth."

- * The American Red Cross expanded its usage of Haemonetics's systems into an additional four Red Cross regions in the second half of the year, with two additional regions set to begin programs in Q1:04.
- * United Blood Systems, the country's second largest blood collector, now collects more than 20% of its total red cells using Haemonetics technology.
- * Based on its first mover advantage, Haemonetics has claimed market leadership in the U.S. with its technology collecting almost 3% of all red cells in the U.S. in fiscal 2003.
- * Market acceptance of the OrthoPAT system for orthopedic surgical cell salvage grew, with end-user growth in the range of 50%. The Company made strong progress through the year in a product enhancement program for the OrthoPAT system.
- * The Company's Fifth Dimension division expanded beyond its North American customer base into Europe. Fifth Dimension also expanded beyond its plasma collector/fractionator customer base to the not-for-profit

blood banking arena. Miscellaneous and service, in which Fifth Dimension revenues are included, grew more than 50%.

Fiscal 2004 Outlook

The Company has recently completed its financial planning process for fiscal 2004, taking into account current market trends and its new product pipeline. Overall fiscal 2004 revenue growth is targeted in the high single digits. By product line, blood bank and plasma disposables growth for fiscal 2004 are expected to be flat. Surgical disposables growth, including both cardiovascular and orthopedic cell salvage, is targeted in the double digits. The Company expects its OrthoPAT system growth to mirror end-user growth by the second half of fiscal 2004. Red cell disposables are anticipated to grow at a rate of 40% to 50%, and result in an increase in U.S. penetration to 4% of all red cells collected.

Haemonetics expects a gross margin in the mid- to high 40% range and an operating margin modestly better than in fiscal 2003. The Company anticipates a tax rate of 36% compared with 26.5% in fiscal 2003, lower interest and other income, and positive impact from foreign exchange of \$0.05 to \$0.10 compared with fiscal 2003. These factors combine to result in anticipated earnings per share flat with those reported in fiscal 2003.

Over the longer term, the Company's product lines sold in mature markets (plasma, platelets, and cardiovascular surgical cell salvage) are expected to have annual revenue growth in the low single digits on a revenue base of more than \$300 million. The newer red cell and OrthoPAT product lines, with combined fiscal 2003 revenues between \$20 and \$25 million, are each growing at 40% to 50% annually.

New Forward-Looking Financial Guidance Policy

Haemonetics also announced that its Board of Directors adopted a formal policy on issuing forward-looking guidance. Beginning with fiscal 2004, the Company will provide forward-looking guidance on anticipated full-year results and targets only. The Company will provide annual revenue guidance on an overall and product line disposables basis, and will continue to provide other key financial data, including capital spending plans, tax rate, and targeted margins. It will also continue to discuss the market, regulatory, and other factors that contribute to its performance.

Mr. Nutter noted that the adoption by the Board of this new policy is a positive development because it allows investors to view the Company as its management and Board review the business. "While some investors may wish to measure our progress on a quarter-by-quarter basis, we believe that by looking at the results of a specific quarter within the context of the full year is more consistent with the way in which we manage the Company. We will strive to provide more information, not less, on the markets we serve, and look forward to aligning all stakeholders' views."

Haemonetics will hold a conference call to review information contained in this release at 9 am (Eastern) tomorrow. Interested parties may listen to the call at (877) 691-0879 or (973) 582-2745 (international). The call will be replayed through May 15, 2003. The replay can be accessed at (877) 519-4471 (domestic) or (973) 341-3080 (international) with PIN 3688863. Additional information will be available on our website prior to the start of the conference call.

About Haemonetics Corporation

Haemonetics (NYSE: HAE) is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collection, plasma collection, and blood component safety. Haemonetics has been recognized by Forbes magazine as one of the nation's best small companies. To learn more about Haemonetics, visit the Company's web site at <http://www.haemonetics.com>.

This release contains forward looking statements that involve risks and uncertainties, including technological advances in the medical field, product demand, market acceptance, regulatory uncertainties, the effect of economic conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates and other risks detailed in the Company's filings with the Securities and Exchange Commission. The forward looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward looking statements.

#

Haemonetics Corporation Financial Summary for the Fourth Quarter FYE03
 Consolidated Statements of Income
 (Unaudited data in thousands, except per share data)

INCOME STATEMENT	3/29/2003	3/30/2002	% Inc/(Dec) vs prior year
NET REVENUES	\$80,881	\$79,053	2.3%
Gross profit	36,218	37,487	(3.4%)
— R&D	4,830	4,564	5.8%
— S, G & A	25,249	21,767	16.0%
Operating expenses	30,079	26,331	14.2%
Operating income	6,139	11,156	(45.0%)
— Interest expense	(965)	(1,050)	(8.1%)
— Interest income	1,103	726	51.9%
— Other income (expense), net	772	(131)	
Income before taxes	7,049	10,701	(34.1%)
Tax expense	2,572	2,998	(14.2%)
NET INCOME	4,477	7,703	(41.9%)
Net income per common share — assuming dilution	\$0.18	\$0.29	(37.9%)
Weighted average number of shares			
— Basic	24,108	26,147	
— Diluted	24,362	26,915	

	Inc/(Dec) vs prior year profit margin %
PROFIT MARGINS:	

Gross profit	44.8%	47.4%	
R&D	6.0%	5.8%	
S, G & A	31.2%	27.5%	
Operating income	7.6%	14.1%	(6.5%)
Income before taxes	8.7%	13.5%	(4.8%)
Net income	5.5%	9.7%	

Haemonetics Corporation Financial Summary for the FYE03
Consolidated Statements of Income
(Unaudited data in thousands, except per share data)

Income Statement:	3/29/2003	3/30/2002	Effect of Special Item (1)	3/30/2002 As adjusted	% Inc/(Dec) vs prior year as adjusted
NET REVENUES	\$336,956	\$319,969		\$319,969	5.3%
Gross profit	154,696	154,834		154,834	(0.1%)
— R&D	19,512	19,512		19,512	0.0%
— S, G & A	97,705	88,874		88,874	9.0%
— Acquired R&D		10,000	10,000		
Operating expenses	117,217	118,386	10,000	108,386	8.1%
Operating income	37,479	36,448	(10,000)	46,448	(19.3%)
— Interest expense	(3,495)	(3,908)		(3,908)	(10.6%)
— Interest income	2,214	3,905		3,905	(43.3%)
— Other income, net	2,409	2,060		2,060	16.0%
Income before taxes	38,607	38,505	(10,000)	48,505	(20.4%)
Tax expense	10,228	10,782	(2,800)	13,582	(24.7%)
Income before cumulative effect of change in acct principle, net of tax	28,379	27,723	(7,200)	34,923	(18.7%)
Cumulative effect of change in acct principle, net of tax (2)		2,304		2,304	(100.0%)
NET INCOME	\$28,379	\$30,027	(\$7,200)	\$37,227	(23.8%)
Income per common share assuming dilution:					
Income per share before cumulative effect of change in acct principle, net of tax	\$1.13	\$1.02	(\$0.27)	\$1.28	
Cumulative per share effect of change in acct principle, net of tax		\$0.09	\$	\$0.09	
Net income per common share	\$1.13	\$1.11	(\$0.27)	\$1.37	
Weighted average number of shares					
— Basic	24,591	26,214	26,214	26,214	
— Diluted	25,048	27,155	27,155	27,155	

PROFIT MARGINS:				Inc/(Dec) vs prior year profit margin % as adjusted
Gross profit	45.9%	48.4%		48.4%
R&D	5.8%	6.1%		6.1%
S,G&A	29.0%	27.8%		27.8%
Operating income	11.1%	11.4%		14.5%
Income before taxes incl cumulative effect of change in acct principle	11.5%	13.0%		16.2%
Net income	8.4%	9.4%		11.6%

The Company's \$10.0 million additional R&D expense was for the acquisition of rights to platelet pathogen reduction technology. Represents cumulative effect of adoption of Statement of Financial Accounting Standard (SFAS) No. 133, "Accounting for Derivative Instruments and Hedging Activities", effective April 1, 2001.

~~Haemonetics Corporation Financial Summary for the Fourth Quarter and FYE03~~

~~Revenue Analysis
(Unaudited data in thousands)~~

	Fourth quarter			Twelve Months Ended		
			%			%
REVENUE ANALYSIS	3 29 03	3 30 02	Inc/(Dec)	3 29 03	3 30 02	Inc/(Dec)
Revenues by Geography						
United States	\$30,541	\$30,514	0.1	\$127,241	\$121,558	4.7
International	50,340	48,530	3.7	209,715	198,411	5.7
Net Revenues	\$80,881	\$79,053	2.3	\$336,956	\$319,969	5.3
Disposable Revenues by Product Line						
Surgical	\$17,365	\$16,948	2.5	\$68,321	\$67,010	2.0
Blood Bank	24,547	23,707	3.5	99,921	102,961	(3.0)
Red Cell	4,662	3,091	50.8	15,542	10,675	45.6
Plasma	26,058	25,549	2.0	114,436	110,178	3.9
Subtotal	\$72,632	\$69,295	4.8	\$298,220	\$290,824	2.5
Equipment	3,870	5,075	(23.7)	20,381	17,040	19.6
Misc & Service	4,379	4,683	(6.5)	18,355	12,105	51.6
Net Revenues	\$80,881	\$79,053	2.3	\$336,956	\$319,969	5.3

Haemonetics Corporation Financial Summary for the FYE03

Consolidated Balance Sheets
(Unaudited data in thousands)

	Period ending		Period ending	
BALANCE SHEET:	3-29-03	3-30-02	3-29-03	3-30-02
Assets				
Cash & available for sale investments	\$ 49,885	\$ 67,549	Liabilities & Stockholders' Equity	
Accounts receivable, net	77,913	63,743	S/T debt & current maturities	\$ 39,005 \$ 31,356
Inventories, net	65,805	67,244	Other current liabilities	61,370 52,742
Other current assets	29,652	34,299	Total current liabilities	100,375 84,098
Total current assets	223,255	232,835	Long term debt	31,612 40,787
Net PP&E	83,988	84,877	Other long term liabilities	3,984 3,212
Other assets	51,965	47,209	Stockholders' equity	223,237 236,824
Total assets	\$359,208	\$364,921	Total liabilities & equity	\$359,208 \$364,921

~~Haemonetics Corporation~~
~~Effect of Foreign Exchange on Earnings Comparisons~~
~~Fourth Quarter Fiscal Year 2003 compared to 2002~~

	Q4 FY 2003	Q4 FY 2002	Inc/(Dec)
Spot Rate Gains/(Losses) on			
— Plan Hedge Contracts included			
— in Operating Income (1)	(\$3,142)	\$ 2,206	(\$5,348)
Difference between constant			
— translation rate and the actual			
— gaap translation rate in the			
— period (2)	1,581	796	785
Effect of Foreign Exchange			
— on Operating Income	(\$1,561)	\$ 3,002	(\$4,563)
Foreign Exchange Transaction			
— Gains/(Losses)	102	(170)	272
Effect on Income Before Taxes	(1,459)	2,832	(4,291)
Income Tax Effect	(533)	793	(1,325)
Effect of Foreign Exchange on			
— Net Income	(\$926)	\$ 2,039	(\$2,966)
Effect on Diluted Earnings Per			
— Common Share	(\$0.04)	\$ 0.08	(\$0.11)
Weighted Average Number of			
— Shares Diluted	24,362	26,915	

~~The Company enters into forward foreign exchange contracts to hedge the anticipated cash flows from forecasted foreign currency denominated revenues. The gains and losses arising from those contracts are excluded from the Company's constant currency performance measures. Those gains and losses include both changes in the spot rate over the life of the contract, and the forward points associated with the contract. The spot rate gains and losses that are realized on those contracts are recorded in sales when the underlying hedged revenues are recorded. The points expensed or earned on those contracts are recorded in other income.~~

~~Under US Generally Accepted Accounting Principles (US GAAP), local functional currency results are translated at the average rate in effect for the period. The average U.S. GAAP rates in effect for the Euro were \$1.06/Euro and \$.88/Euro in the fourth quarter of fiscal year '03 and '02, respectively, and for the Japanese Yen were 119 JPY/\$1 and 133 JPY/\$1 in the fourth quarter of fiscal year '03 and '02. While much of our product costs are incurred in US dollars, approximately 60% of our revenues are denominated in local functional currencies, primarily the Euro and the Japanese Yen. In order to compare our consolidated results from one period to another we translate all periods at the same Euro and Yen exchange rates.~~

~~The rates used are our current constant currency rates established at the beginning of the current fiscal year.~~

~~The constant currency rates used in arriving at the above constant currency results were 130JPY/\$1 for the Japanese Yen and \$0.91/Euro for the Euro.~~

~~We do not place significance on the actual constant currency results, but employ them for the primary purpose of comparing one periods performance against another while holding currency constant.~~

Haemonetics Corporation
 Effect of Foreign Exchange on Earnings Comparisons
 Full Fiscal Year 2003 compared to 2002

	FY 2003	FY 2002	Inc/(Dec)
Spot Rate Gains/(Losses) on Plan Hedge Contracts included in Operating Income (1)	(\$4,483)	\$ 8,136	(\$12,619)
Difference between constant translation rate and the actual gaap translation rate in the period (2)	3,866	5,285	(1,419)
Effect of Foreign Exchange on Operating Income	(\$617)	\$13,421	(\$14,038)
Foreign Exchange Transaction Gains/(Losses)	621	(227)	848
Effect of Foreign Exchange on Income before taxes	4	13,194	(13,190)
Income Tax Effect	1	3,694	(3,693)
Effect of Foreign Exchange on Net Income	3	9,500	(\$9,497)
Effect on Diluted Earnings Per Common Share	\$0.00	\$0.35	\$0.34
Weighted Average Number of Shares Diluted	24,362	27,155	

The Company enters into forward foreign exchange contracts to hedge the anticipated cash flows from forecasted foreign currency denominated revenues. The gains and losses arising from those contracts are excluded from the Company's constant currency performance measures. Those gains and losses include both changes in the spot rate over the life of the contract, and the forward points associated with the contract.

The spot rate gains and losses that are realized on those contracts are recorded in sales when the underlying hedged revenues are recorded. The points expensed or earned on those contracts are recorded in other income.

Under US Generally Accepted Accounting Principles (U.S. GAAP), local functional currency results are translated at the average rate in effect for the period. The average U.S. GAAP rates in effect for the Euro were \$.99/Euro and \$.88/Euro in fiscal year '03 and fiscal year '02, respectively, and for the Japanese Yen were 122 JPY/\$1 and 124 JPY/\$1 in fiscal year '03 and fiscal year '02. While much of our product costs are incurred in U.S. dollars, approximately 60% of our revenues are denominated in local functional currencies, primarily the Euro and the Japanese Yen. In order to compare our consolidated results from one period to another we translate all periods at the same Euro and Yen exchange rates.

The rates used are our current constant currency rates established at the beginning of the current fiscal year.

The constant currency rates used in arriving at the above constant currency results were 130JPY/\$1 for the Japanese Yen and \$0.91/Euro for the Euro.

We do not place significance on the actual constant currency results, but employ them for the primary purpose of comparing one periods performance against another while holding currency constant.

